GLAXO HERPES THERAPY SALES GAIN 4% IN U.S. IN FIRST HALF DESPITE ZOVIRAX GENERIC COMPETITION; COMPANY URGING EUROPEAN GOVERNMENTS TO ALLOW DTC ADS
Executive Summary
Glaxo Wellcome's anti-herpetic drug sales gained 4% in the U.S. for the first six months of 1997 despite the expiration of the patent for the company's flagship herpes therapy Zovirax in April, the company indicated at a July 31 press conference in London.